This study reevaluates PaBQU and DBQU regimens in mouse models, finding they have lesional liability in complex lesions, which may explain their failure in a human trial.

DOI 10.64898/2026.09.15.751879

mouseproteomics

𝕏 PostBluesky

MicrobiologyAntimicrobial Agents and ChemotherapyPeer-reviewedSep 30, 2025

Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis

Nathan Peroutka‐Bigus, Michael S. Sherman, Firat Kaya…·Gregory T. Robertson

This study evaluates replacing linezolid with spectinamide MBX-4888A in the Nix-TB regimen for tuberculosis in a mouse model, showing potential for reduced adverse effects.

1 citation

mouseexperimental assay

𝕏 PostBluesky

MicrobiologyAntimicrobial Agents and ChemotherapyPeer-reviewedMar 26, 2025

Contribution of front-line, standard of care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease

Nathan Peroutka‐Bigus, Elizabeth J. Brooks, Michelle E. Ramey…·Gregory T. Robertson

The paper evaluates the effectiveness of standard TB drugs in mice, showing rifampin's critical role in killing bacteria and preventing resistance.

3 citations

mouseexperimental assay

𝕏 PostBluesky